—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Natera Inc (NTRA) — chart, structure and Closelooknet read

The Closelooknet read

Natera develops molecular diagnostic tests that read DNA fragments from blood or tissue to flag disease markers or genetic risk. Its lines include Signatera, which tracks circulating tumour DNA to monitor cancer recurrence and treatment response; Panorama, a non-invasive prenatal screen; Horizon, a carrier screening test; Empower, a hereditary cancer screen; and Prospera, which checks for rejection after organ transplants.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on NTRA

What this diary said about Natera Inc, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we hold

BookPositionSinceResult
AI Buildout 50 shares · average entry $206.25 — +76.4%

Model books as of 5 Nov 2026; wikifolio positions from the official wikifolio data, entries in euros. Results are unrealised, before any exit. A record of what the diary does, not a recommendation to do the same.

Signals for this name

Every Closelooknet reading that exists for NTRA, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 · AI Users — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-11-05

DayWeekMonth3 months
NTRA−7.0%−16.6%−8.0%+12.9%
Longevity & Healthspan−3.9%−3.5%+2.7%—
HALO Growth 100−2.8%−1.2%+0.4%—

Against the index: 15.4 pts behind on the week, 8.4 pts behind on the month; against its Longevity & Healthspan sleeve 10.7 pts behind on the month.

AI Users · as of 2026-11-05

DayWeekMonth3 months
NTRA−7.0%−16.6%−8.0%+12.9%
Research, Design & Development−2.6%−2.3%+9.1%—
AI Users−1.5%+1.2%+8.0%—

Against the index: 17.8 pts behind on the week, 16.0 pts behind on the month; against its Research, Design & Development sleeve 17.1 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Dossier, “Agentic Application Software: The SaaSpocalypse Map” (2026-02-27)

Mentioned on Closelooknet

Where NTRA appears in the diary — 1 piece, newest first. Every link is our own writing.

Go deeper

Long reads

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 44/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-05
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 73th percentile of the window, -21.7% over 20 sessions. Factor regime → 2026-11-04
  • Sector × region Health care in US: +0.5% week · +9.5% month · +12.0% quarter · +26.5% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-05
  • Sovereign pressure Index -2.05 · down 2.95 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-05
How it trades on rate days beta 1.07 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How NTRA has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.07 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Natera Inc moved 1.07% on average · correlation 0.21 · higher than 86% of US names
  • Beta, last 3 months −0.21 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.69% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +4.61% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against NTRA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Natera Inc

NTRA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Natera develops molecular diagnostic tests that read DNA fragments from blood or tissue to flag disease markers or genetic risk. Its lines include Signatera, which tracks circulating tumour DNA to monitor cancer recurrence and treatment response; Panorama, a non-invasive prenatal screen; Horizon, a carrier screening test; Empower, a hereditary cancer screen; and Prospera, which checks for rejection after organ transplants. It also licenses Constellation, a cloud platform letting other laboratories run its methods under their own name. Natera serves hospitals, physician practices, laboratories and drugmakers, and is based in Austin, Texas.
Where it sits in the stack
Natera sits on the user side of AI, inside the AI Users index, which tracks companies applying AI to strengthen businesses they already run, in the Research, Design & Development section covering discovery and new product work. It has disclosed that algorithms call results on its Panorama prenatal screen, documented in February 2025 with sensitivity and false-positive figures for one condition. It also disclosed, in April 2021, that algorithms call results on its broader prenatal cfDNA test, cutting the share of inconclusive calls by half, though it did not quantify any related cost saving. In both processes the company states the AI decides the result itself rather than only assisting a technician.
Who it is priced against
Natera sits in Closelooknet's HALO Growth 100, the growth index outside the megacaps, in the Longevity & Healthspan sleeve, where demand follows demographic trends. The group spans GLP-1 drug names, gene-editing platforms, diagnostics-at-scale companies and biopharma compounders: Eli Lilly, Regeneron, Vertex, Zealand Pharma, Amgen, Illumina, Novo Nordisk and Gerresheimer. The market also names Exact Sciences as a comparable diagnostics-at-scale competitor.
Why Closelooknet tracks it
Natera holds two index seats: the AI Users Research, Design & Development section and the HALO Growth 100. It carries a Closelooknet score across three modules so far, strongest on momentum and weakest on valuation. The diary has named it once, in a February 2026 dossier on agentic application software that grouped Natera with other names on valuation multiples.
What the diary watches
The diary watches whether Natera's planned in-house foundation model, disclosed in August 2025 for biomarker work, stratification and trial matching, reaches production and changes the economics of its existing testing lines.

Natera Inc (NTRA) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 44/100 composite (momentum 85, quality 24, valuation 6) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-25. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 4 analyst actions on the wire · latest: price target by Roth Capital, 2026-10-22 · last print 2026-11-05

The Street on this name

Analyst actions and the latest print for NTRA from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Roth Capital — target 475 Target set to $475 (+18.3% to spot) 2026-10-22
  • Price target Canaccord — target 500 from 375 Target raised to $500 from $375 (+27.1% to spot) 2026-10-19
  • Price target Guggenheim — target 475 from 360 Target raised to $475 from $360 (+13.6% to spot) 2026-10-01
  • Latest print EPS -0.42 against -0.28 expected — a -49.3% miss 2026-11-05

4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What NTRA pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +9.6% in FY2025 354 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-06

Quick answers

What is Natera Inc (NTRA)?

Natera Inc trades as NTRA on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-06.

Is NTRA in a Closelooknet index?

Yes — Natera Inc is a constituent of HALO Growth 100, as of 2026-11-06.

What is Natera Inc's Closelooknet composite score?

44 out of 100, with momentum 85, quality 24 and valuation 6 sub-scores, as of 2026-11-06. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does NTRA trade against its moving averages?

Natera Inc trades 2.8% above its 50-day and 45.7% above its 200-day moving average (2.9% below its 20-day). As of 2026-11-04 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is NTRA doing against its Closelooknet index?

Over the past month Natera Inc is −8.0% against +0.4% for the HALO Growth 100 — 8.4 points behind its index, as of 2026-11-05. Its Longevity & Healthspan sleeve is +2.7% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Natera Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Natera Inc (NTRA) sits 10.6% below its 52-week high, 2.8% above its 50-day average; Regeneron Pharmaceuticals Inc (REGN) is 6.2% below, Vertex Pharmaceuticals Inc (VRTX) is 3.5% below, Zealand Pharma A/S (ZEAL.CO) is 57.4% below, as of 2026-11-04. Put any of them next to NTRA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Natera Inc trade when bond yields rise?

Over the past year Natera Inc had a beta of 1.07 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 86% of US names. On the 10 sessions in which long bonds fell most it moved −0.69% on average, against −0.74% for the S&P 500. As of 2026-11-05; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Natera Inc?

Natera Inc appears in 1 Closelooknet piece as of 2026-11-06, most recently Dossier: Agentic Application Software: The SaaSpocalypse Map (2026-02-27). What Closelooknet said most recently: Veeva (VEEV) · Tempus AI (TEM) · Natera (NTRA) · Intuitive Surgical (ISRG) Valuation Multiples vs. (Dossier, 2026-02-27). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

Does Closelooknet hold Natera Inc?

Yes — AI Buildout: 50 shares · average entry $206.25, +76.4% unrealised (book of 2026-11-05). A record of what the diary does, not a recommendation to do the same.

What does Natera Inc do?

Natera develops molecular diagnostic tests that read DNA fragments from blood or tissue to flag disease markers or genetic risk. Its lines include Signatera, which tracks circulating tumour DNA to monitor cancer recurrence and treatment response; Panorama, a non-invasive prenatal screen; Horizon, a carrier screening test; Empower, a hereditary cancer screen; and Prospera, which checks for rejection after organ transplants. It also licenses Constellation, a cloud platform letting other laboratories run its methods under their own name. Natera sits in Closelooknet's HALO Growth 100, the growth index outside the megacaps, in the Longevity & Healthspan sleeve, where demand follows demographic trends. The group spans GLP-1 drug names, gene-editing platforms, diagnostics-at-scale companies and biopharma compounders: Eli Lilly, Regeneron, Vertex, Zealand Pharma, Amgen, Illumina, Novo Nordisk and Gerresheimer. The market also names Exact Sciences as a comparable diagnostics-at-scale competitor. (Company snapshot of 2026-10-25.)

Where does Natera Inc sit in the AI build-out?

Natera sits on the user side of AI, inside the AI Users index, which tracks companies applying AI to strengthen businesses they already run, in the Research, Design & Development section covering discovery and new product work. It has disclosed that algorithms call results on its Panorama prenatal screen, documented in February 2025 with sensitivity and false-positive figures for one condition. It also disclosed, in April 2021, that algorithms call results on its broader prenatal cfDNA test, cutting the share of inconclusive calls by half, though it did not quantify any related cost saving. In both processes the company states the AI decides the result itself rather than only assisting a technician. Natera holds two index seats: the AI Users Research, Design & Development section and the HALO Growth 100. It carries a Closelooknet score across three modules so far, strongest on momentum and weakest on valuation. The diary has named it once, in a February 2026 dossier on agentic application software that grouped Natera with other names on valuation multiples. (Company snapshot of 2026-10-25.)

Does Natera Inc pay a dividend?

No cash distribution shows in Natera Inc’s price series over the last three years. The share count rose 9.6% over the fiscal year. As of 2026-11-05; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Natera Inc recently?

The most recent analyst action on Natera Inc on the Closelooknet wire is a price target by Roth Capital on 2026-10-22 (target 475). 4 actions on the analyst wire since 2026-08-13: 4 target changes. Its latest earnings print on the wire, 2026-11-05: EPS -0.42 against -0.28 expected — a -49.3% miss. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for NTRA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.